Pfizer Stock Drops 3.16% Despite RSV Vaccine Approval for Adults 18-59, Trading Volume Ranks 41st

On April 1, 2025, Pfizer (PFE) experienced a 3.16% decline in its stock price, with a trading volume of $1.342 billion, ranking 41st in the day's market activity.

Pfizer's RSV vaccine, ABRYSVO, has received expanded approval from the European Commission. This approval now includes adults aged 18 to 59, in addition to the previously approved age group of 60 and older. The vaccine is designed to prevent lower respiratory tract disease caused by RSV, a common respiratory virus that can lead to severe illness or even death.

This expanded approval is significant as it broadens the vaccine's indication to include a larger population, potentially reducing the burden of RSV in future seasons. The decision is based on results from the pivotal phase 3 clinical trial, which demonstrated the safety, tolerability, and immunogenicity of ABRYSVO in adults at risk of RSV-associated lower respiratory tract disease.

Pfizer's Chief International Commercial Officer, Alexandre de Germay, expressed enthusiasm about the approval, highlighting the potential of ABRYSVO to substantially reduce the burden of RSV. The vaccine's expanded authorization in the EU is a significant step forward in public health, offering protection to a broader range of individuals.